Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14487500 | 0.89 | TRPM2 (0.46) | LMNATSHRGAANPSR1TDP1 | |
| SCHEMBL18854207 | 0.87 | LMNA (0.39) | LMNATSHRGAANPSR1TDP1 | |
| SCHEMBL15708707 | 0.86 | LMNA (0.60) | LMNATSHRGAANPSR1TDP1 | |
| SCHEMBL18325701 | 0.85 | GABRP (0.35) | LMNATSHRGAASMN1; SMN2HSD17B10 | |
| SCHEMBL15730151 | 0.77 | LMNA (0.31) | LMNATSHRGAANPSR1ALDH1A1 | |
| SCHEMBL21562972 | 0.76 | GABRP (0.34) | GAANPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL18325699 | 0.73 | ALDH1A1 (0.40) | LMNATSHRGAANPSR1SMN1; SMN2 | |
| SCHEMBL14555336 | 0.73 | — | — | |
| SCHEMBL18317199 | 0.70 | LMNA (0.49) | LMNATSHRGAANPSR1TDP1 | |
| SCHEMBL15724338 | 0.70 | LMNA (0.44) | LMNATSHRGAANPSR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202353-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20160368881-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368881-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | LMNA 3258/4885TSHR 4700/4885GAA 24/4885 |
| US-10202353-B2 | Therapeutic compounds | RPL35, SARS1, HAVCR2 | LMNA 3179/4885TSHR 4727/4885GAA 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.